Table 3.
Subgroup analysis of the primary endpoint in VICTORIA trial.
| Subgroup | Hazard ratio | 95% CI |
|---|---|---|
| All patients | 0.90 | 0.82–0.92 |
| Sex | ||
| Male | 0.90 | 0.81–1.00 |
| Female | 0.88 | 0.73–1.08 |
| Age (years) | ||
| <65 | 0.81 | 0.70–0.95 |
| >65 | 0.94 | 0.84–1.06 |
| <75 | 0.84 | 0.75–0.94 |
| >75 | 1.04 | 0.88–1.21 |
| Race | ||
| White | 0.91 | 0.81–1.02 |
| Asian | 0.91 | 0.75–1.11 |
| Black | 0.85 | 0.56–1.28 |
| Other | 0.80 | 0.57–1.11 |
| HF decompensation events | ||
| Intravenous diuretics (previous 3 months) | 0.78 | 0.60–1.02 |
| HFH (previous 3 months) | 0.93 | 0.84–1.04 |
| HFH (previous 3–6 months) | 0.85 | 0.67–1.07 |
| NYHA functional class | ||
| I–II | 0.91 | 0.80–1.04 |
| III–IV | 0.87 | 0.77–0.99 |
| LVEF (%) | ||
| <35% | 0.88 | 0.79–0.97 |
| ≥35% | 0.96 | 0.81–1.14 |
| <40% | 0.88 | 0.80–0.97 |
| ≥40% | 1.05 | 0.81–1.36 |
| eGFR (mL/minute/1.73 m 2) | ||
| ≤30 | 1.06 | 0.83–1.34 |
| >30 to ≤60 | 0.84 | 0.73–0.96 |
| >60 | 0.92 | 0.80–1.07 |
| Sacubitril/valsartan use at baseline | ||
| Yes | 0.88 | 0.70–1.11 |
| No | 0.90 | 0.81–0.99 |
| NT-proBNP level (pg/mL) | ||
| Quartile 1: ≤1.556 | 0.78 | 0.62–0.99 |
| Quartile 2: 1.556–2.816 | 0.73 | 0.60–0.90 |
| Quartile 3: 2816–5314 | 0.82 | 0.69–0.99 |
| Quartile 4: >5314 | 1.16 | 0.99–1.35 |
eGFR, estimated glomerular filtration rate; HF, heart failure; HFH, heart failure hospitalization; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
Table adapted from the VICTORIA trial.9